Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study.

Clin Transl Oncol · 2021 · PMC8390421 · PMID 34109562

Europe PMC DOI

hedged sentence

0.2228

closest p · 4.5× alpha

0.2228

boldest claim

The sentences

did not reach statistical significanceP = 0.2228not close (p > 0.1)

Treatments Pharmacological treatment for CS The mean total annual cost of pharmacological treatment for CS was higher in the uncontrolled CS (€25,924.80) than in the controlled CS group (€18,219.15) but the difference did not reach statistical significance ( P = 0.2228) (Table 4 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.